Asset profile
Enfortumab Vedotin
Antibody–drug conjugate
Approvedregulatory verdict
Evidence outlook
Approved: muscle invasive bladder cancer (MIBC) (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Enfortumab Vedotin: this drug | Phase 3 | Antibody–drug conjugate | Nectin-4 | ||
| SHR-A2102 | Phase 3 | Antibody–drug conjugate | Nectin-4 | ||
| Zelenectide Pevedotin | Phase 2 | Peptide | Nectin-4 | ||
| 225Ac-AKY-1189 | Phase 1 | Radiopharmaceutical | Nectin-4 | ||
| IPH4502 | Phase 1 | Antibody–drug conjugate | Nectin-4 | ||
| LY4052031 | Phase 1 | Antibody–drug conjugate | Nectin-4 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 |
…and 50 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(52 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
December 2026 (3)
Phase 1Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma …Active not recruiting
Est. primary completion 2026-12-01 · NCT04963153 · CT.gov ↗
What to watch
Phase 2Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm …Recruiting
Est. primary completion 2026-12-16 · NCT05756569 · CT.gov ↗
What to watch
Phase 4Metastatic Urothelial CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06862219 · CT.gov ↗
What to watch
2027 (22)
January 2027 (2)
February 2027 (1)
Phase 1/2Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder CancerRecruiting
Est. primary completion 2027-02-01 · NCT04724018 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Adenoid Cystic CarcinomaRecruiting
Est. primary completion 2027-03 · NCT06891560 · CT.gov ↗
What to watch
April 2027 (2)
May 2027 (1)
Phase 1/2Metastatic Urothelial Carcinoma, Urothelial NeoplasmsActive not recruiting
Est. primary completion 2027-05-31 · NCT05845814 · CT.gov ↗
What to watch
June 2027 (5)
Phase 1Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05614739 · CT.gov ↗
What to watch
Phase 1Advanced Urothelial Cancer, Metastatic Urothelial CarcinomaRecruiting
Est. primary completion 2027-06 · NCT07484022 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-06 · NCT05239624 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-06 · NCT06906822 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-06-02 · NCT05868265 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)Not yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
Early phase / not applicableUrothelial Carcinoma (UC), Peripheral Nerve DiseaseNot yet recruiting
Est. primary completion 2027-09-01 · NCT07629700 · CT.gov ↗
What to watch
Phase 1/2Advanced Bladder CancerRecruiting
Est. primary completion 2027-09-24 · NCT06434350 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Bellini Carcinoma, Collecting Duct Carcinoma, Renal Medullary CarcinomaRecruiting
Est. primary completion 2027-10 · NCT06302569 · CT.gov ↗
What to watch
Phase 2Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell TumorsRecruiting
Est. primary completion 2027-10-01 · NCT06041503 · CT.gov ↗
What to watch
November 2027 (4)
Phase 2Muscle Invasive Bladder Urothelial CarcinomaRecruiting
Est. primary completion 2027-11 · NCT06809140 · CT.gov ↗
What to watch
Phase 1Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma …Recruiting
Est. primary completion 2027-11-13 · NCT04878029 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2027-11-30 · NCT07139977 · CT.gov ↗
What to watch
Phase 2Muscle-invasive Bladder CancerRecruiting
Est. primary completion 2027-11-30 · NCT07475806 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial CarcinomaRecruiting
Est. primary completion 2027-12-28 · NCT07421700 · CT.gov ↗
What to watch
2028 (17)
January 2028 (2)
Phase 1Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer, Bladder CancerNot yet recruiting
Est. primary completion 2028-01 · NCT07217496 · CT.gov ↗
What to watch
Phase 1/2Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8Recruiting
Est. primary completion 2028-01-31 · NCT06470282 · CT.gov ↗
What to watch
March 2028 (4)
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-03 · NCT06356155 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-03 · NCT07183319 · CT.gov ↗
What to watch
Phase 1/2Metastatic Urothelial Carcinoma, Locally Advanced Urothelial CarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT06483334 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid NeoplasmRecruiting
Est. primary completion 2028-03-31 · NCT06311214 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2High Grade Urothelial Carcinoma, Bladder Cancer, Urothelial Carcinoma BladderRecruiting
Est. primary completion 2028-06 · NCT05656235 · CT.gov ↗
What to watch
Phase 2Advanced Urothelial CarcinomaNot yet recruiting
Est. primary completion 2028-06-01 · NCT07374549 · CT.gov ↗
What to watch
Phase 2Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 …Recruiting
Est. primary completion 2028-06-01 · NCT06104618 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial CarcinomaActive not recruiting
Est. primary completion 2028-07-01 · NCT05923190 · CT.gov ↗
What to watch
Phase 4Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma …Recruiting
Est. primary completion 2028-07-01 · NCT06764095 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma …Recruiting
Est. primary completion 2028-08-07 · NCT07087860 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2028-08-12 · NCT07157956 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial CarcinomaRecruiting
Est. primary completion 2028-09-01 · NCT07221942 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2028-09-30 · NCT06394570 · CT.gov ↗
What to watch
Phase 2Advanced Small Bowel AdenocarcinomaRecruiting
Est. primary completion 2028-09-30 · NCT07347314 · CT.gov ↗
What to watch
2029 (5)
February 2029 (1)
Phase 2Urothelial Carcinoma (UC)Not yet recruiting
Est. primary completion 2029-02 · NCT07643519 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Penile Squamous Cell Carcinoma (PSCC)Recruiting
Est. primary completion 2029-05 · NCT07110038 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1/2Locally Advanced or Metastatic Malignant Solid TumorsRecruiting
Est. primary completion 2029-06-30 · NCT07287995 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma …Recruiting
Est. primary completion 2029-07-16 · NCT07667335 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2Metastatic Colorectal Cancer, Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-09 · NCT06553885 · CT.gov ↗
What to watch
2030 (3)
March 2030 (1)
Phase 3Urothelial Cancer, Urinary Bladder NeoplasmsRecruiting
Est. primary completion 2030-03-31 · NCT07566156 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Metastatic Urothelial CancerActive not recruiting
Est. primary completion 2030-04 · NCT03547973 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Advanced Bladder CancerNot yet recruiting
Est. primary completion 2030-12 · NCT07346053 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.